Heparin-binding Protein: An early marker of circulatory failure in sepsis

Clinical Infectious Diseases

Volumn 49, Issue 7, 2009, Pages 1044-1050

  Linder, Adam ^a   Christensson, Bertil ^a   Herwald, Heiko ^a   Björck, Lars ^a   Åkesson, Per ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEPARIN BINDING PROTEIN; HYPERTENSIVE AGENT; INTERLEUKIN 6; LACTIC ACID; PROCALCITONIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HYPOTENSION; INFECTION; ISCHEMIA; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; BLOOD PROTEINS; C-REACTIVE PROTEIN; CALCITONIN; CARRIER PROTEINS; FEMALE; HUMANS; INTERLEUKIN-6; LACTATES; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SEPSIS; SHOCK; YOUNG ADULT;

EID: 70349929473     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605563     Document Type: Article

References (19)

1. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420:885-891
2. Gautam N, Olofsson AM, Herwald H, et al. Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat Med 2001;7:1123-1127 (Pubitemid 33010020)
3. Tapper H, Karlsson A, Mörgelin M, Flodgaard H, Herwald H. Secretion of heparin-binding protein from human neutrophils is determined by its localization in azurophilic granules and secretory vesicles. Blood 2002;99:1785-1793 (Pubitemid 34533054)
4. Herwald H, Cramer H, Mörgelin M, et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 2004;116:367-379 (Pubitemid 38366314)
5. McNamara C, Zinkernagel AS, Macheboeuf P, Cunningham MW, Nizet V, Ghosh P. Coiled-coil irregularities and instabilities in group A Streptococcus M1 are required for virulence. Science 2008;319:1405-1408
6. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60.
7. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365: 63-78.
8. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-150
9. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-1596 (Pubitemid 43810035)
10. Shapiro NI, Howell MD, Talmor D, et al. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med 2005;45:524-528 (Pubitemid 40591784)
11. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341:515-518 (Pubitemid 23066085)
12. Selberg O, Hecker H, Martin M, Klos A, Bautsch W, Kohl J. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med 2000; 28: 2793-2798 (Pubitemid 30676525)
13. Gibot S, Kolopp-Sarda MN, Bene MC, et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004; 141:9-15. (Pubitemid 38857333)
14. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003;31:1737-1741 (Pubitemid 36714230)
15. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655
16. Rasmussen PB, Björn S, Hastrup S, et al. Characterization of recombinant human HBP/CAP37/azurocidin, a pleiotropic mediator of inflammation-enhancing LPS-induced cytokine release from monocytes. FEBS Lett 1996:390:109-112 (Pubitemid 26233278)
17. Lindmark A, Garwicz D, Rasmussen PB, Flodgaard H, Gullberg U. Characterization of the biosynthesis, processing, and sorting of human HBP/CAP37/azurocidin. J Leukoc Biol 1999;66:634-643 (Pubitemid 29489891)
18. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377 (Pubitemid 34940725)
19. Shapiro NI, Trzeciak S, Hollander JE, et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 2009;37:96-104.